Gray market is often used to describe products sold outside familiar medical or institutional channels. The phrase does not establish whether a particular transaction is lawful, whether its material is genuine or whether a product is suitable for treatment. Those questions require more precise facts.

Separate three kinds of uncertainty

Regulatory uncertainty concerns the product, intended use and applicable jurisdiction. Quality uncertainty concerns identity, manufacturing, contamination and stability. Clinical uncertainty concerns whether the intervention's benefits outweigh its risks in a particular population. Resolving one does not automatically resolve the others.

FDA's communication on unapproved GLP-1 products illustrates this separation. It warns about consumer products falsely labeled for research and explains concerns with unapproved versions of named compounds. A research-use disclaimer cannot make human-use claims disappear. FDA concerns with unapproved GLP-1 drugs

A policy development is not an approval

The October 30, 2026 Federal Register notice announces a nonbinding draft HHS policy addressing conditional enforcement discretion for certain section 503A compounding. It is not an FDA approval decision, does not establish clinical effectiveness and does not create general permission for retail research products to be used in people. The exact policy conditions and state requirements need specialist review. October 30 2026 Federal Register notice on draft HHS peptide policy

Even a lawful compounding situation should not be described as equivalent to an approved product. Similarly, a genuine laboratory reagent can remain inappropriate for administration to humans.

For AXON's educational content, precision is more useful than a reassuring market label. Identify the actual substance, the type of supplier, the intended use and the evidence supporting the specific claim. If one of those is unknown, say so. This article neither endorses a supplier nor provides a legal determination for an individual purchase. It explains why market terminology cannot replace scientific evidence or a product-specific regulatory assessment.